Scholarlink

<p>Drug development is a multifaceted and time-intensive process that spans candidate discovery, formulation, pharmacokinetics (PK), and evaluation of therapeutic efficacy and safety. Nuclear medicine imaging—particularly positron emission tomography (PET) and single-photon emission computed tomography (SPECT)—enables noninvasive, quantitative, and dynamic assessments of drug behavior at the molecular and systemic levels. These modalities visualize real-time biodistribution, tissue PK, target engagement, and treatment response, addressing the limitations of conventional approaches such as plasma sampling and invasive tissue biopsies. This review summarizes the contributions of PET and SPECT across the drug development continuum. Representative case studies illustrate their applications in characterizing molecular kinetics, informing pharmacokinetic and pharmacodynamic (PK/PD) relationships, evaluating target specificity, and detecting early off-target effects. We also discuss how imaging-derived metrics can support earlier go/no-go decisions, enhance preclinical-to-clinical translation through a shared quantitative framework across species and disease models, and inform individualized therapeutic strategies. Overall, PET and SPECT serve as core tools that improve the accuracy, safety, and efficiency of modern drug development for molecularly targeted therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Unlocking drug development: the distinctive roles of PET and SPECT imaging from molecular kinetics to therapeutic response

  • 期刊论文

  • 发表日期：

    2025年12月20日

查看全文
  • Sun Mi Park,
  • Joo Yeon Park,
  • Tae Sup Lee,
  • Ji-Young Kim,
  • Hai-Jeon Yoon,
  • Bom Sahn Kim,
  • Byung Seok Moon

摘要

Drug development is a multifaceted and time-intensive process that spans candidate discovery, formulation, pharmacokinetics (PK), and evaluation of therapeutic efficacy and safety. Nuclear medicine imaging—particularly positron emission tomography (PET) and single-photon emission computed tomography (SPECT)—enables noninvasive, quantitative, and dynamic assessments of drug behavior at the molecular and systemic levels. These modalities visualize real-time biodistribution, tissue PK, target engagement, and treatment response, addressing the limitations of conventional approaches such as plasma sampling and invasive tissue biopsies. This review summarizes the contributions of PET and SPECT across the drug development continuum. Representative case studies illustrate their applications in characterizing molecular kinetics, informing pharmacokinetic and pharmacodynamic (PK/PD) relationships, evaluating target specificity, and detecting early off-target effects. We also discuss how imaging-derived metrics can support earlier go/no-go decisions, enhance preclinical-to-clinical translation through a shared quantitative framework across species and disease models, and inform individualized therapeutic strategies. Overall, PET and SPECT serve as core tools that improve the accuracy, safety, and efficiency of modern drug development for molecularly targeted therapies.